- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00242593
Rosiglitazone Effects on Cognition for Adults in Later Life (RECALL)
The Effects of Rosiglitazone on Cognition in Patients With MCI
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study will examine the effects of the insulin-sensitizing agent rosiglitazone on learning and memory for 120 patients diagnosed with MCI. Participants will be randomized to an 18-month trial of rosiglitazone or placebo, followed by a 2-month washout period. At screening and at treatment month 18, all participants will undergo an oral glucose tolerance test (OGTT) to estimate pre- and post- treatment insulin sensitivity and β-cell function. Cognitive measures and blood samples for biochemical assays will be obtained at baseline, treatment months 6, 12, and 18, and washout (two months after completing treatment).
During treatment, participants will have safety labs drawn and receive physical assessment of any adverse events, changes in health status, or changes in medication; initially these visits will be done at weeks 2 and 4, and then every three months. For months in which a safety visit is not scheduled, telephone monitoring to assess any health concerns will be conducted.
All participants enrolled in the primary study will be approached to participate in an MRI substudy; patients will undergo serial brain MRI before treatment and following 18 months of rosiglitazone or placebo, using three-dimensional T1-weighted images. Comparison of MCI patients receiving rosiglitazone and placebo will be conducted to determine whether the rate of medial temporal lobe (MTL) and whole brain atrophy is altered following treatment.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Banner Alzheimer Institute
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- UCLA Alzheimer's Disease Center
-
-
Washington
-
Seattle/Tacoma, Washington, Estados Unidos, 98108
- University of Washington/VA Puget Sound Health Care System
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- MCI diagnosis: Participants will be diagnosed with MCI by consensus of a team of physicians and neuropsychologists experienced in the diagnosis of MCI, using the Petersen (Petersen, 1999, 2001) criteria for amnestic MCI or multiple domain MCI with amnestic features: a) the presence of subjective memory complaints, evaluated via detailed patient history and informant interview, b) objective verification of memory impairment as measured by neuropsychological tests, c) normal general cognitive function, d) intact or only mildly impaired activities of daily living, and e) absence of dementia per NINCDS/ADRDA and/or DSM-IV criteria
Exclusion Criteria:
The following exclusion criteria will be used, based on initial physical examination, medical history, lab work, and oral glucose tolerance test (OGTT) results:
- Diagnosis of diabetes or other relevant glucoregulatory disorders
- Use of any oral anti-diabetic compounds
- Clinically significant elevations in liver function
- Significant neurological disease that might affect cognition, other than MCI, including Alzheimer's disease, large-vessel stroke, Parkinson's disease, multiple sclerosis, recent severe head injury (loss of consciousness for more than 30 minutes in the past year), or remote head injury resulting in permanent cognitive or neurological sequelae
- History or current evidence of congestive heart failure (CHF)
- History of documented ischemic cardiac disease, i.e., angina, MI, angioplasty, stent, or CABG
- History of cardiac or vascular surgery, or significant arrhythmia within the last year; or planned major intervention such as cardiac surgery or stenting. A history of cardiac surgery for non-ischemic indications (i.e., valve repair or replacement) greater than one year prior to enrollment is not exclusionary if all other criteria are met
- Significant ECG abnormalities including heart rate less than 50 or greater than 100 beats per minute (dependent upon the individual's general health); any previously unrecognized arrhythmia requiring further intervention
- Significant peripheral edema at the time of screening
- Significant medical illness or organ failure, including but not limited to renal disease, hepatic disease, and unstable cardiac disease
- Regular current use of antipsychotic, anticonvulsive, anxiolytic, or sedative medications; antidepressant medications are not exclusionary, provided the individual does not have current major depression
- A current diagnosis of major depression or other significant psychiatric comorbidity
- Clinically significant anemia at the time of screening
- Fasting triglyceride level greater than 400
- Fasting glucose 125 or greater, or two-hour glucose value greater than 199 during the OGTT; participants will be notified if their fasting blood sugar (monitored every 3 months) exceeds 125, and they will be withdrawn from further participation if their fasting blood sugar exceeds 125 for two consecutive months
- For the MRI substudy, additional exclusion criteria include 1) previous exposure to work involving the cutting or grinding of metal, 2) the presence of a pacemaker, aneurysm clip, or other implanted metal device that would prohibit MRI procedures, and 3) significant history of claustrophobia
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: A
oral rosiglitazone 4 mg twice daily for 18 months
|
4 mg twice daily oral rosiglitazone or placebo pill for 18 months
Otros nombres:
|
Comparador de placebos: B
placebo pill twice daily for 18 months
|
4 mg twice daily oral rosiglitazone or placebo pill for 18 months
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Cognitive measures: delayed list recall, Stroop Interference test
Periodo de tiempo: every 6 months for 18 months, again 2 at months post-treatment (20 months)
|
every 6 months for 18 months, again 2 at months post-treatment (20 months)
|
Biological outcomes: plasma insulin, IDE, AB40, AB42, inflammatory cytokines, and F2-isoprostanes
Periodo de tiempo: every 6 months for 18 months, again 2 at months post-treatment (20 months)
|
every 6 months for 18 months, again 2 at months post-treatment (20 months)
|
MRI outcome: Whole brain and medial temporal lobe atrophy rate
Periodo de tiempo: baseline and 18 months
|
baseline and 18 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Cognitive measures: ADAS-cog total score, story recall verbal fluency, paired associate learning, SOPT, rating scales
Periodo de tiempo: every 6 months for 18 months, again 2 at months post-treatment (20 months)
|
every 6 months for 18 months, again 2 at months post-treatment (20 months)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Suzanne Craft, PhD, University of Washington/VA Puget Sound Health Care System
Publicaciones y enlaces útiles
Publicaciones Generales
- Goldstein BJ. Rosiglitazone. Int J Clin Pract. 2000 Jun;54(5):333-7.
- Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med. 2001;52:239-57. doi: 10.1146/annurev.med.52.1.239.
- Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol. 2003 Oct;60(10):1394-9. doi: 10.1001/archneur.60.10.1394.
- Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001 Apr 15;21(8):2561-70. doi: 10.1523/JNEUROSCI.21-08-02561.2001.
- Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17(1):27-45. doi: 10.2165/00023210-200317010-00003.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IA0087
- 1R01AG025502-01A1 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .